Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

NCT02102698 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Tourette's Syndrome

Interventions

DRUG: Ecopipam

Sponsor

Emalex Biosciences Inc.

Collaborators

[object Object]